TOP TIERMARKET NEWSWIRE

News & sentiment

IONIS PHARMACEUTICAL (IONS) — News & AI sentiment

IONIS PHARMACEUTICAL (IONS) news roundup. 7 stories in the past week, 21 over 30 days. Average 30-day sentiment is 63.1/100. Recent insider activity (SEC Form 4, 90-day window): 1 purchases totalling $1.1M and 2 sales totalling $61K — net buying of $997K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

7

avg sentiment 64.7/100

30d stories

21

avg sentiment 63.1/100

Insider net (90d)

$997K

1 buys · 2 sells

Congress (90d)

0

0 buys · 0 sells

IONS news in the last 24 hours, 7 days, 30 days and 90 days

How much IONS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IONS stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	7	64.7/100	IONS headlines →
Last 30 days	21	63.1/100	IONS headlines →
Last 90 days	92	53.3/100	IONS headlines →

Latest stories on IONS

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

Seeking Alpha64 · neutralanalyst

3d ago

Ionis Advances IgA Nephropathy Program With Positive Phase 3

TipRanks74 · bullishproduct/pr

5d ago

IONIS PHARMACEUTICALS INC (IONS) files 8-K

SEC 8-K50 · neutralgeneral

5d ago

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

StockTitan74 · bullishproduct/pr

5d ago

Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment

Stocktwits News64 · neutralproduct/pr

6d ago

Ionis treatment of Dravet syndrome granted FDA orphan status

The Fly64 · neutralproduct/pr

7d ago

Ionis Pharmaceuticals stock price target maintained at $100 by H.C. Wainwright on HBV approval

Investing.com Analyst Ratings63 · neutralanalyst

7d ago

Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia

Seeking Alpha64 · neutralanalyst

Oct 21

BMO upgrades Ionis Pharmaceuticals stock rating on sHTG opportunity

Investing.com Analyst Ratings64 · neutralanalyst

Oct 21

5-star BMO analyst upgrades Ionis ahead of Q3 report

The Fly64 · neutralanalyst

Oct 21

IONIS PHARMACEUTICALS INC (IONS) files 8-K

SEC 8-K50 · neutralgeneral

Oct 21

Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital

The Fly63 · neutralanalyst

Oct 21

3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside

TipRanks64 · neutralanalyst

Oct 21

Ionis Pharmaceuticals recent selloff overdone, says Citi

The Fly63 · neutralanalyst

Oct 21

Ionis Pharmaceuticals partner GSK announces FDA approval of Hibsago

The Fly74 · bullishproduct/pr

Oct 21

Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight

PR Newswire58 · neutralproduct/pr

Oct 20

Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond James

The Fly34 · bearishanalyst

Oct 20

Ionis Pharmaceuticals Gets CHMP Backing for Tryngolza in Severe Hypertriglyceridemia.

MarketWatch74 · bullishproduct/pr

Oct 16

Ionis Pharmaceuticals says CHMP adopts positive opinion on tryngolza

The Fly74 · bullishproduct/pr

Oct 16

Ionis Pharmaceuticals upgraded to Buy from Neutral at UBS

The Fly64 · neutralanalyst

Oct 15

Alnylam vs. Ionis: Here's the Better Bad-News Buy

The Motley Fool63 · neutralanalyst

Oct 10

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data

Investing.com Analyst Ratings56 · neutralanalyst

Sep 24

BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data

Investing.com Analyst Ratings56 · neutralanalyst

Sep 23

Roche, Ionis succeed in late-stage trial for kidney disease therapy

Seeking Alpha73 · bullishproduct/pr

Sep 23

Canaccord reiterates Ionis stock rating on positive trial results

Investing.com Analyst Ratings61 · neutralanalyst

Sep 23

Open IONS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →